We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
BXRX =MC $52 M--FDA Decision in Q1 for attractive Drug
An SI Board Since December 2019
Posts SubjectMarks Bans Symbol
10 2 0 BXRX
Emcee:  BioHero Type:  Moderated
Market-Cap $49 Million-- Cash $19 Million or untill end 2020 -- Shares Out 9.1 Million -- Potential FDA approval for their lead drug Anjeso (non-opioid pain reliever ) in Q1 2020 which has HUGE market potential .MASSIVE underpriced Low float stock with significant upside potential here ..My target is $20+ by end of next year .GL

Baudax Bio (BXRX)

Market Cap 49 M
Cash $19 M
Price $5.45

Shares Out 9.1 M

New Presentation (december 2019)

Janney starts Baudax Bio at buy; fair value estimate $12

Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.

She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”

 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
10Still a massive buying opportunity at current laughable valuation of only $87 miBioHero-February 21
9Soaring with heavy volume. Day high: 10.14. [graphic]Alejandroo Green-February 21
817 days till FDA decision ,, still time to get in cheapBioHero-February 3
7FDA approval is very likely this time ,, Approval would make this undiscovered sBioHero-January 27
6Any dip here is a great buying opp ahead of the FDA decision next month ,stock lBioHero-January 24
5FDA DECISION NEXT MONTH ...News out today (FDA) has set a PDUFA goal date of BioHero-January 22
4Baudax Bio Inc. (BXRX) PT Raised to $12 at Oppenheimer streetinsider.comBioHero-January 21
3GREAT buying opportunity here ahead of the NDA resubmission likely to hit the wiBioHero-January 8
2NDA resubmission likely to come next week this will attract new investors so i tBioHero-12/20/2019
1massive upside potential on this undiscovered stockBioHero-12/19/2019
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):